Molecules on the Move: Reversible BTKi in MS, THR-beta Agonist in NASH, and More
Other articles you may be interested in
Tackling MedChem Bias One Functional Group at a Time
Functional groups that medicinal chemists don't encounter regularly often face greater scrutiny compared to more common ones. In his Flash Talk, Gilles Ouvry challenges these biases and presents data on four uncommon functional groups that required extra convincing to gain acceptance. Here we supply a PDF download of his slides for our members.
Roles of the Chloro and Methoxy Groups in Drug Discovery
In this Flash Talk, Yoshihiro Ishihara discussed the beneficial effects of chloro and methoxy substituents on intermolecular interactions, as well as the unique advantages and disadvantages of employing these substituents in drug discovery.
As part of our Flash Talk webinar series, we present a PDF of Yoshihiro Ishihara's slide deck and full text questions and answers from his talk, entitled "Roles of the Chloro and Methoxy Groups in Drug Discovery." Check out the recording of the talk on our Drug Hunter YouTube channel.
Key Clinical Compound Updates from November 2024
This summary of major clinical updates from November 2024 covers FDA approvals, the initiation of new clinical trials, notable trial outcomes for key drug candidates, and news on paused and discontinued trials and programs.
Advancing Macrocycles in Drug Discovery
In this Flash Talk, Katarina Leftheris highlights how advances in our understanding of ADME requirements, screening technologies, formulations development and computational modeling helped macrocycles back on the center stage of the industry.
As part of our Flash Talk webinar series, we present a PDF of Katarina Letheris'slide deck, entitled "Advancing Macrocycles in Drug Discovery". Check out the recording of the talk on our Drug Hunter YouTube channel.
Patent Highlights: Nurr1 and Nur77 Modulators, STAT3 Inhibitors/Degraders, CDK2 Molecular Glue Degraders, ERAP1 Modulators, and More!
This article highlights key patents published in September 2024, covering a range of therapeutic targets and mechanisms. It includes Nurr1 and Nur77 modulators for oncology applications, STAT3 inhibitors and CRBN-based STAT3 degraders for modulating STAT3 signaling in cancer, and CDK2 molecular glue degraders for estrogen receptor-positive breast cancer resistant to CDK4/CDK6 inhibitors. Additionally, it features ERAP1 modulators for addressing autoimmune diseases, APOL1 inhibitors for APOL1-mediated kidney diseases, and novel NEK7 inhibitors targeting the NLRP3 inflammasome pathway.